Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Poon

Showing results (361-370 of 401) with videos related to

Pageof 41
Sort By:
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2016
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular CarcinomaThomas C C Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.
World Journal of Gastroenterology|May 30, 2013
High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patientsTan To Cheung, Sheung Tat Fan, See Ching Chan, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinomaLing Xiao Liu, Nikki P Lee, Vivian W Chan, et al.
Gut|December 16, 2016
<i>TSC1/2</i> mutations define a molecular subset of HCC with aggressive behaviour and treatment implicationDaniel W H Ho, Lo K Chan, Yung T Chiu, et al.
Hepatobiliary Surgery and Nutrition|June 23, 2023
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021Tan-To Cheung, Simon Chun-Ho Yu, Stephen L Chan, et al.
Journal of Gastroenterology and Hepatology|June 15, 2012
Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011Joseph J Y Sung, Enders K W Ng, Jaw-Town Lin, et al.
JAMA|July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trialAndrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
Acta Crystallographica. Section C, Structural Chemistry|November 4, 2022
Complexes of 2,4,6-trihydroxybenzoic acid: effects of intramolecular hydrogen bonding on ligand geometry and metal binding modesBrendan F Abrahams, Christopher J Commons, Timothy A Hudson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinomaXiao Qi Wang, John M Luk, Mercè Garcia-Barcelo, et al.
Pageof 41

Showing results (361-370 of 401) with videos related to

Sort By:
Pageof 41
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2016
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular CarcinomaThomas C C Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.
World Journal of Gastroenterology|May 30, 2013
High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patientsTan To Cheung, Sheung Tat Fan, See Ching Chan, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinomaLing Xiao Liu, Nikki P Lee, Vivian W Chan, et al.
Gut|December 16, 2016
<i>TSC1/2</i> mutations define a molecular subset of HCC with aggressive behaviour and treatment implicationDaniel W H Ho, Lo K Chan, Yung T Chiu, et al.
Hepatobiliary Surgery and Nutrition|June 23, 2023
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021Tan-To Cheung, Simon Chun-Ho Yu, Stephen L Chan, et al.
Journal of Gastroenterology and Hepatology|June 15, 2012
Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011Joseph J Y Sung, Enders K W Ng, Jaw-Town Lin, et al.
JAMA|July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trialAndrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
Acta Crystallographica. Section C, Structural Chemistry|November 4, 2022
Complexes of 2,4,6-trihydroxybenzoic acid: effects of intramolecular hydrogen bonding on ligand geometry and metal binding modesBrendan F Abrahams, Christopher J Commons, Timothy A Hudson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinomaXiao Qi Wang, John M Luk, Mercè Garcia-Barcelo, et al.
Pageof 41